This 10-year Medline search of English-language articles describing experimental and clinical studies on chemokines, cardiopulmonary bypass (CPB) and systemic or multiorgan failure revealed that chemokines are significantly involved in the pathogenesis of post-CPB syndrome. The post-CPB inflammatory response depends upon recruitment and activation of inflammatory cells. Leucocyte recruitment is a well-orchestrated process that involves several protein families, including pro-inflammatory cytokines, adhesion molecules and chemokines. Current anti-inflammatory therapies mostly act on the cells that have already been recruited. A more efficient therapy might be the prevention of excessive recruitment of particular leucocyte populations by antagonizing chemokine receptors which might act upstream of the current anti-inflammatory agents. The chemokines, which are a cytokine subfamily of chemotactic cytokines, participate in recognizing, recruiting, removing and repairing inflammation. As chemokines target specific leucocyte subsets, antagonism of a single chemokine ligand or receptor would be expected to have a circumscribed effect, thereby endowing the antagonist with a limited side-effect profile. Chemokines should be considered as possible targets for therapeutic intervention.
Introduction
The use of cardiopulmonary bypass (CPB) is believed to be responsible for some of the major postoperative complications following open heart surgery. Fever, leucocytosis, general capillary leak syndrome and the appearance of multiorgan dysfunction involving mainly the heart and lungs are known features of the postpump syndrome which is thought to be responsible for a significant amount of post-CPB morbidity and mortality (1, 2) . The exposure of a patient's blood to the surface of the extracorporeal circulatory device is a unique medical condition, which, together with the systemic reperfusion after the discontinuation of the CPB, is invariably associated with a dramatic inflammatory reaction (3, 4) . This process has been previously studied in great detail, but its immunoregulatory characteristics remain uncertain. Early reports had focused on the changes in serum pro-inflammatory cytokine activity during and after CPB in both children and adults, alterations that appeared similar to those occurring in sepsis (2, 3, 5, 6) . These proinflammatory mediators include the tumour necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-8 (IL-8) which are responsible for the complex interactions between various types of leucocytes. Together with the complement, coagulation and the fibrinolytic systems, they were blamed for the high incidence of organ dysfunction following CPB (1, 2, 4, 7) .
It is currently accepted that inflammatory cytokines together with endothelial activation and endothelialleucocyte interactions play an important role in the induction of systemic inflammatory response (3, 5, 8, 9) ( Table 1 ). The resultant inflammatory response causes increased permeability of membranes and total body water, leading to respiratory distress and severe multiorgan failure.
The neutrophil is known for its tissue-destructive potential in various inflammatory disorders following ischaemia and reperfusion, among them, especially, acute respiratory distress syndrome and myocardial injury. This deleterious effect is associated with neutrophil-mediated release of active enzymes that can cause tissue destruction (10) . Indeed, one of the first reactions to reperfusion is the rapid accumulation of specific subpopulations of leucocytes near the capillary endothelium in the reperfused organs.
The chemokines, a group of cytokines with powerful chemotactic and activating effects on leucocytes, were recently described as having a role in the post-CPB acute inflammatory response (Figure 1) . Insofar as attraction of leucocytes is essential for the continuation of the inflammatory process, chemokines are thus considered important activators in the propagation of both acute and chronic inflammatory processes (11, 12) . It is assumed that chemokines are not only responsible for leucocyte accumulation, but also play an active role in mediating their transendothelial migration. This action is performed through the chemokinesÕ ability to increase the affinity between leucocytes and integrins, a group of molecules on the surface of the leucocyte that mediate the interactions of leucocytes and endothelial cells (11) . Chemokines selectively attract different leucocyte subsets: some act specifically on neutrophils or eosinophils while others act on monocytes or T cells.
The chemokines, of which more than 40 types have been identified to date, are 8-10 kDa proteins that can be categorized into various families by the relative position of four cysteine amino acid residues that form two disulphide bonds and are responsible for the tertiary structure of the chemokine molecule.
The chemokines are distinguished from other cytokines by being the only members of the cytokine family that act on the superfamily of G-proteincoupled serpentine receptors. There are at least four families of chemokines, of which only two have been Table 1 Definitions for key terms in the systemic inflammatory response related to cardiopulmonary bypass and cardiac surgery Inflammation -Humoural and cellular response of the body to tissue injury. Systemic inflammatory response syndrome (SIRS) -Nonspecific, generalized inflammatory process which is defined by the presence of two or more of the following: temperature >38°C or <36°C, heart rate >90 bAEmin
, respiratory rate >20 breathsAEmin )1 or PaCO 2 <4.2 kPa (32 mmHg), leucocytes >12, <40.10 9 l )1 or >10% immature (band) forms. Sepsis -SIRS with documented infection. Cytokines -Soluble proteins and polypeptides which play a role as paracrine messengers of the immune system and are produced and secreted by cells of the immune system or the endothelium as a response to various stressors. Proinflammatory cytokines -Cytokines, which facilitate a wide range of inflammatory processes. The most known of the proinflammatory cytokines include: tumour necrosis factor (TNF), IL-1, IL-6, IL-8, IL-12. Anti-inflammatory cytokines -Cytokines, which inhibit inflammatory processes by counteracting the effects of the proinflammatory cytokines or reducing their production. Major anti-inflammatory cytokines include IL-4, IL-6, IL-10, IL-11 and IL-13. Chemokines -Cytokines, which are being secreted near sites of inflammation by tissue cells and are responsible for the control of movement and migration of inflammatory cells to tissues. studied extensively (11) . In the C-X-C or a-chemokine family, the first two cysteine amino acid residues are separated by one different amino acid residue (amino acid X). This chemokine group is represented by IL-8, and is clustered as a group on chromosome 4. Another group of chemokines, the C-C or b-chemokine family, possesses two cysteine amino acid residues which are in juxtaposition to each other and are exemplified by the monocyte chemoattractant protein-1 (MCP-1).
The genes for this group of chemokines are clustered on human chromosome 17 (12) . The a-chemokines induce neutrophil chemotaxis, whereas the b-chemokines do not act on neutrophils but are chemotactic for monocytes, eosinophils, basophils and T-cell subsets. Among the b-chemokines, the MCP-1 and the Regulated Upon Activation Normal T Cell Expressed and Secreted (RANTES) types are two chemokines which can attract and activate monocyte and macrophages. The chemotactic activity of these chemokines is mediated by their ability to bind to a dozen already identified specific G-protein-coupled cell-surface receptors on different target cells (13) . These receptors are present on some cells while they are inducible on others. For example, whereas chemokine receptors are constitutively expressed on monocytes, they are expressed on lymphocytes only after stimulation by IL-2 (14) . The increased secretion of chemokines by different cells during inflammation and their powerful ability to induce cell activation and migration result in selective accumulation of leucocytes in the inflamed area. An early stimulus for the production of the chemokines are pro-inflammatory cytokines, such as TNF and IL-1, which are secreted early in the beginning of the inflammatory process (15) . This chemokine-mediated increased leucocyte concentration constitutes an important link in the chain of the propagation of the inflammatory response.
a-Chemokines and CPB
Investigations in animal models of systemic inflammation have proved the essential involvement of IL-8 in mediating acute inflammation in different organs post-CBP. IL-8 is considered the prototype of a-chemokines. Although monocytes were the first cells to be identified as a rich source of IL-8, it has now been established that most somatic cells can synthesize IL-8. Hepatocytes, endothelial cells, fibroblasts, epithelial cells, mesothelial cells, neutrophils and host cell lines have also been shown to produce IL-8 (16) . The ability of cells to express IL-8 is stimulus-specific, i.e. IL-1 and TNF stimulation effectively causes IL-8 secretion.
During an inflammatory response, the macrophages and neutrophils serve as the first-line of host defence, responding to the inflammatory challenge with the rapid generation of both IL-1 and TNF. These two early response cytokines can stimulate the surrounding stromal and parenchymal cells to synthesize chemokines, such as IL-8 and MCP-1, thus enabling the continuation of the inflammatory process by attracting leucocytes. IL-8 is a 69-79 amino acid member of the C-X-C family of chemokines that possess potent neutrophil chemotactic and activating potentials (17) . This 8-kDa peptide was the first chemoattractant to have been identified as being specific for neutrophils. In response to a variety of inflammatory stimuli (cytokines, hypoxia, ischaemia-reperfusion), IL-8 is induced on most cell types, including endothelium, epithelium, leucocytes and glial cells (18, 19) . IL-8 interacts with G-protein-coupled receptors on neutrophils to stimulate chemotaxis, changes in morphology, adhesion and diapedesis as well as the release of lysosomal enzymes (20) . In the presence of inflammatory leucocytes, IL-8 increases vascular permeability both in vitro and in vivo (17, 20) . IL-8 can activate neutrophils as well as T lymphocytes and controls their trafficking as well. Complement activation is also known to promote IL-8 expression (10, 21, 22) .
Investigations in animal models of systemic inflammation have proved the essential involvement of IL-8 in mediating acute inflammation in different organs post-CBP. In the presence of inflammatory leucocytes, IL-8 increases vascular permeability both in vitro and in vivo. More than any of the other chemokines, IL-8 further induces neutrophil activation and migration into the peripheral tissue, and it is considered responsible for some of the negative consequences of CPB in children (6, (23) (24) (25) . It was suggested that the sequence of anoxia/hyperoxia that is inherent to procedures that involve ischaemia-reperfusion, such as CPB, is a strong stimulus for the production of IL-8. This takes place through the induction of the expression of the IL-8 gene via NF-jB transcriptional activation in the hypoxic endothelial cells (26) , leading to increased production of IL-8 and the associated end-organ damage, i.e. lung injury as a result of pulmonary leucocyte sequestration (8) . A considerable body of clinical evidence has also documented that the myocardium is a major source of IL-8 during reperfusion after ischaemia or after acute myocardial infarction (27) . This increased IL-8 production is associated with the duration of the myocardial ischaemia during the CPB period (28) .
Postoperative levels of troponin I, a highly specific marker of myocardial injury, correlated strongly with IL-8 values in patients undergoing coronary artery bypass grafting with or without CPB (29) . In addition, the stimulus of CPB alone was shown to be sufficient in inducing IL-8 mRNA production in the human myocardium (27) . These reports are consistent with several studies that describe an early upregulation of IL-8 after CPB.
Finn et al. demonstrated the association between longer bypass time and higher IL-8 levels in children (25) . The rise of IL-8 commences towards the end of the bypass and peaks 1-3 h thereafter, and its levels correlate with the length of bypass. The authors suggested that the IL-8 plays a role in the pathophysiology of the capillary leak syndrome that takes place through neutrophil degranulation (25) . Tarnok et al. compared changes in the levels of IL-8 in children undergoing CPB in comparison with children undergoing major cardiovascular surgery without CPB (30) . They found that the CPB group exhibited peak levels of IL-8 between 4 h and 2 days after surgery, with values that ranged between 6.4 and 1771 pgAEml )1 (30).
Riesenberg et al. showed that the release of IL-8 was higher in patients with complicated acute myocardial infarction than in those with uncomplicated acute myocardial infarction, indicating that IL-8 is a major contributor to the priming of neutrophils following myocardial ischaemic events and that it may subsequently exacerbate the extent of the injury to the whole body as well (31) .
We recently demonstrated an association between increased IL-8 levels in response to CPB and the above-described intraoperative and early postoperative course in children undergoing corrective cardiac surgery (32) . Increased levels of IL-8 were found to be directly associated with the duration of surgical and aortic clamp times. In addition, we showed that the IL-8 levels were significantly higher in children who required prolonged inotropic support postoperatively. The results of this study added more lines of evidence to a growing body of data describing a robust inflammatory response to CPB where IL-8 has a major role.
b-Chemokines and CPB
The b-chemokines, of which MCP-1 and RANTES have been the most studied, constitute another important group of cytokines that were recently demonstrated to be involved in the post-CPB syndrome. MCP-1, a powerful chemotactic cytokine for monocytes (33) , is generated mainly within the endothelium but it can also be produced by a variety of leucocytes and fibroblasts (34) . The gene expression of MCP-1 is regulated by transcription factors of the NF-jB family that can be induced by various pro-inflammatory cytokines (i.e. TNF and IL-1) as well as by oxidative and mechanical stress (35) . RANTES, which also belongs to the C-C chemokine family, is produced mainly by T cells but can also by released by platelets; its regulation is also controlled by the NF-jB transcription mechanism (16) . RANTES has a potent chemotactic activity for T cells, eosinophils, basophils and mast cells.
In a prospective study on 16 children who underwent corrective heart surgery that involved the use of CPB, MCP-1 appeared in the systemic circulation in the early post-CPB phase and peaked 1 h after the bypass (36) . In addition, MCP-1 levels correlated with the children's clinical outcome, i.e. higher MCP-1 and lower RANTES levels were measured in children with prolonged CPB time, longer surgical times, or the need for inotropic support (34) . Elevated MCP-1 levels were described in adults after CPB as well (37) (38) (39) . Kawahito et al. (37) and Ernofsson et al. (38) reported that MCP-1 appeared in the systemic circulation in the early post-CPB period and that it reached peak levels at 3 h after bypass. Kumar et al. (40) showed that MCP-1 and its mRNA levels reached their highest levels by the third hour following reperfusion injury of the ischaemic myocardium. These high levels persisted for as long as 2 days after the reperfusion (40) . MCP-1 may contribute to deleterious sequelae in a number of ways. It is the main chemoattractant for mononuclear phagocytes, NK cells, T cells, mast cells and basophils, and has been implicated in transendothelial monocyte recruitment to sites of inflammation (11) . The gathered monocytes, in turn, can express tissue factor, thus activating the extrinsic coagulation pathway (41) . In addition, it has been shown that MCP-1 is capable of inducing monocytes into an increased respiratory burst activity and lysosomal enzyme release (11) . These activities might also contribute to multi-organ damage which develops post-CPB. Furthermore, by increasing the expression of integrins MCP-1 can stimulate the complex process of monocyte adhesion to the capillary endothelium (16, 18) . Nevertheless, final proof for MCP-1 effects following CPB awaits additional studies that will utilize agents that block the activity of this cytokine in vivo and examine the resultant haemodynamic effects.
The data on RANTES after CPB are scarce. Published data on plasma RANTES levels have been obtained primarily from studies of both acute and chronic inflammatory disorders (11, 41, 42) . We have previously shown that RANTES, a potent stimulator of macrophages and monocytes, decreased in the serum following CPB and that these lower levels reflected patientsÕ outcome (36) . The reduced RAN-TES levels and the associated complicated clinical course (i.e. increase need for system-oriented support) could provide new insight into the immunoregulatory characteristics of the postpump syndrome (36) . These results also can explain the previous reports describing changes in lymphocyte subsets following CPB (43) (44) (45) . According to Ide et al., the total number of T lymphocytes was markedly reduced during CPB (44) . Thus, we speculate that reduced RANTES activity corresponds to reduced lymphocyte counts, acting as a mediator of lymphocyte depletion following CPB, as recently reported by Hisatomi et al. (45) .
Are chemokines valid targets for therapy?
The development of approaches to control the inflammatory response following cardiac surgery is the focus of considerable research efforts. Current anti-inflammatory therapies mostly act on the cells that have already been recruited. In fact, certain treatments that are at present successful at treating inflammation have an effect on the recruitment of leucocytes. Anti-inflammatory approaches that target proinflammatory cytokines, adhesion molecules, matrix metalloproteinases have been studied in vitro and tested in many animal models and several clinical studies in the past (13) . A more efficient therapy might be the prevention of excessive recruitment of particular leucocyte populations by antagonizing chemokine receptors, which might act upstream of the current anti-inflammatory agents (13) . Direct antimediator therapy that focus upon chemokines following CPB offers new approaches. However, this field is still too young to answer this question, and animal models and clinical studies have yet to be designed to address this issue.
Conclusion
The inflammatory response following CPB is dependent upon elicitation and activation of inflammatory cells leading to tissue injury. This is verified by the important interaction of earlyresponse cytokines, adhesion molecules and chemokines in the orchestration of the recruitment of neutrophils into the tissues. The discovery of the C-X-C supergene family has greatly enhanced our understanding of the biology of leucocyte recruitment into tissues. These protein mediators of inflammation play an important role during the recognition, recruitment, removal and repair phases of inflammation.
The data on the role of chemokines in the pathogenesis of the post-CPB syndrome are still incomplete. There is little information on chemokine regulation after CPB and none on how this regulation might be helpful in abrogating multisystem dysfunction which sometimes occurs following the use of CPB in cardiac surgery. Animal models of CPB-induced inflammation might prove valuable in answering these unresolved questions.
